NASHVILLE, TN
4 risk indicators measuring financial stability and operational resilience
Sign in with your work email to view Tuckman-Chang indicators
Sign In — Free (10 views/day)DIALYSIS CLINIC INC, founded in 1971, is a major nonprofit in the Health Care sector that reported $736.4M in total revenue in fiscal year 2023.
THE PRIMARY RESPONSIBILITY OF DIALYSIS CLINIC INC. (DCI) IS TO PROVIDE COMPREHENSIVE AND SPECIALIZED CARE TO PATIENTS LIVING WITH CHRONIC KIDNEY DISEASE (CKD) AND END STAGE RENAL DISEASE (ESRD).
THE DIALYSIS DIVISION IS THE PRINCIPAL ACTIVITY OF OUR COMPANY AND IS PRIMARILY INVOLVED WITH PROVIDING KIDNEY DIALYSIS AND RELATED SERVICES FOR INSURED AND UNINSURED PATIENTS. RENAL DIALYSIS IS NOT...
THE DIALYSIS DIVISION IS THE PRINCIPAL ACTIVITY OF OUR COMPANY AND IS PRIMARILY INVOLVED WITH PROVIDING KIDNEY DIALYSIS AND RELATED SERVICES FOR INSURED AND UNINSURED PATIENTS. RENAL DIALYSIS IS NOT AN ELECTIVE MEDICAL PROCEDURE, BUT A LIFE-SUSTAINING TREATMENT FOR PEOPLE LIVING WITH KIDNEY FAILURE. PROVIDING THESE MEDICALLY-NECESSARY TREATMENTS FURTHERS OUR EXEMPT PURPOSE OF PROVIDING QUALITY OUTPATIENT CARE FOR ALL PATIENTS WITH END-STAGE RENAL DISEASE, WHICH INCLUDES THE APPLICATION OF COMPANY RESOURCES FOR SCIENTIFIC AND EDUCATIONAL PURPOSES FOR THE PREVENTION, EARLY DETECTION, AND TREATMENT OF RENAL DISEASE. DURING FY24, 2,199,052 DIALYSIS PROCEDURES WERE PERFORMED. A SIGNIFICANT PORTION OF OUR DIALYSIS CHARGES ARE COVERED BY MEDICARE AND STATE MEDICAID PROGRAMS, WHILE THE REMAINING COSTS ARE PAID BY THIRD PARTY INSURERS, AND CHARITY CARE. CHARITY CARE IS PROVIDED TO PATIENTS WHO MEET CERTAIN CRITERIA UNDER OUR CHARITY CARE POLICY WITHOUT CHARGE OR AT AMOUNTS LESS THAN OUR ESTABLISHED RATES.
THE LAB DIVISION PROVIDES SPECIALIZED LABORATORY TESTING AND DIAGNOSTIC PROCEDURES FOR DIALYSIS FACILITIES AND PATIENTS WITH KIDNEY DISEASE AND RENAL FAILURE. A VARIETY OF LABORATORY TESTS TO ANALYZE...
THE LAB DIVISION PROVIDES SPECIALIZED LABORATORY TESTING AND DIAGNOSTIC PROCEDURES FOR DIALYSIS FACILITIES AND PATIENTS WITH KIDNEY DISEASE AND RENAL FAILURE. A VARIETY OF LABORATORY TESTS TO ANALYZE DIFFUSED TOXINS FROM THE BLOOD ARE NECESSARY TO MONITOR THE CLINICAL COURSE OF PATIENTS AND THE OVERALL EFFECTIVENESS OF RENAL DIALYSIS. THESE TESTS ARE NECESSARY IN THE TREATMENT OF RENAL DISEASE, AND FURTHERS OUR EXEMPT PURPOSE OF PROVIDING QUALITY CARE FOR PATIENTS WITH CHRONIC RENAL DISEASE BY CONTINUALLY IMPROVING OUR PROCESSES IN MEASURING LEVELS OF KIDNEY FUNCTION TO PRODUCE OPTIMAL PATIENT OUTCOMES. FOR FYE 2024, 775,068 PATIENT TESTS WERE PERFORMED.
THE SUPPLY AND PHARMACY DIVISION PROVIDES MEDICAL SUPPLIES, INCLUDING BUT NOT LIMITED TO NUTRITIONAL SUPPLEMENTS, DRUGS, AND HOME DIALYSIS SUPPLIES FOR DCI FACILITIES AND PROVIDES PRESCRIPTION...
THE SUPPLY AND PHARMACY DIVISION PROVIDES MEDICAL SUPPLIES, INCLUDING BUT NOT LIMITED TO NUTRITIONAL SUPPLEMENTS, DRUGS, AND HOME DIALYSIS SUPPLIES FOR DCI FACILITIES AND PROVIDES PRESCRIPTION MEDICATIONS FOR DCI EMPLOYEES.
Financial Health Score (300–850) · Liquidity · Solvency · Sustainability · Efficiency
Sign in to view Trantor Score and financial metrics
Liquidity (40%) • Solvency (30%) • Sustainability (20%) • Efficiency (10%)
Sign In — Free (10 views/day)| 2023 | 2022 | Change | |
|---|---|---|---|
| Revenue | $736,387,532 | $728,068,130 | +0.0% |
| Expenses | $720,249,084 | $744,815,158 | 0.0% |
| Net Income | $16,138,448 | $-16,747,028 | -2.0% |
Comprehensive financial analysis: Altman Z-Score, liquidity, solvency, sustainability, efficiency, and growth metrics
Financial Distress Indicator
Liquidity & Cash Position
Sign in to view all financial metrics
Altman Z-Score • Liquidity Ratios • Solvency Analysis • Growth Indicators • Efficiency Metrics
Sign In| Name | Title | Hours/Week | Role | Reportable Comp | Other Comp | Total |
|---|---|---|---|---|---|---|
| DOUGLAS JOHNSON MD | VICE CHAIRMAN | 39.00 |
Director
|
$445,892 | $38,586 | $484,478 |
| H KEITH JOHNSON MD | CHAIRMAN OF THE BOARD | 32.00 |
Director
|
$11,684 | $6,675 | $51,359 |
| JAMES PERRY | DIRECTOR | 9.00 |
Director
|
$0 | $12,882 | $12,882 |
| KEN JOHNSON | DIRECTOR | 1.00 |
Director
|
$0 | $0 | $0 |
| DONOVAN SCHULTZ | PRESIDENT | 38.00 |
Officer
|
$468,242 | $25,496 | $493,738 |
| STUART REDPATH | CHIEF OPERATING OFFICER | 40.00 |
Officer
|
$447,199 | $38,586 | $485,785 |
| MARY HOBEIKA | CHIEF STRATEGY OFFICER | 40.00 |
Officer
|
$310,350 | $14,314 | $324,664 |
| JOE SWEARINGEN | CHIEF FINANCIAL OFFICER | 39.00 |
Officer
|
$271,319 | $35,939 | $307,258 |
| JAMES E ATTRILL | VICE PRESIDENT | 15.00 |
Officer
|
$61,787 | $10,802 | $72,589 |
| AMIT NAHATA | PHYSICIAN | 40.00 |
Highest
|
$691,509 | $34,986 | $726,495 |
| JOSEPH DEJONCKHEERE | PHYSICIAN | 40.00 |
Highest
|
$585,292 | $34,907 | $620,199 |
| RAPHAEL HIGGINBOTHAM | PHYSICIAN | 40.00 |
Highest
|
$520,934 | $18,547 | $539,481 |
| AYMAN GENEIDY | PHYSICIAN | 40.00 |
Highest
|
$477,474 | $37,074 | $514,548 |
| MOSTAFA AMR | PHYSICIAN | 40.00 |
Highest
|
$460,624 | $25,134 | $485,758 |
| WILLIAM WOOD | FORMER PRESIDENT | 0.00 |
|
$417,734 | $16,883 | $434,617 |
| Year | Revenue | Expenses | Assets | Net Income |
|---|---|---|---|---|
| 2024 | $736,387,532 | $720,249,084 | $697,727,403 | $16,138,448 |
| 2023 | $728,068,130 | $744,815,158 | $695,959,374 | $-16,747,028 |
| 2022 | $727,825,569 | $848,633,522 | $649,708,855 | $-120,807,953 |
| 2021 | $753,633,577 | $745,611,982 | $795,817,725 | $8,021,595 |
| 2020 | $765,633,140 | $744,985,667 | $782,995,317 | $20,647,473 |
| 2019 | $739,130,845 | $731,344,904 | $714,063,423 | $7,785,941 |
| 2018 | $704,855,490 | $702,895,895 | $708,661,934 | $1,959,595 |
Compare DIALYSIS CLINIC INC with other nonprofits in Tennessee and across the country.